Friday Mar 7
Medivation Price Target Lowered to $85.00 at Ubs Ag
The firm currently has a "buy" rating on the stock. UBS AG's price target points to a potential upside of 22.43% from the stock's previous close.
The Motley Fool
Was Medivation's Quarter a Disaster?
Sales of Xtandi jumped double digit percentages quarter-after-quarter in 2013, but the company expects that winning streak will end as sequential growth in the U.S. slips to mid single digits this year.
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Medivation Inc. shares fell 14.92 percent to close at $71.91 a share Friday. The stock traded between $70.87 and $75.98 on volume of 8.02 million shares traded.
Medivation Receives "Buy" Rating from Aegis
's stock had its "buy" rating reaffirmed by equities research analysts at Aegis in a research note issued to investors on Friday, Stock Ratings Network.com reports.
Medivation, Inc. Reports Fourth Quarter And Year-End 2013 Financial...
Medivation, Inc. today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2013.
The Motley Fool
Why Medivation, Inc. Shares Tumbled
So what: For the quarter, Medivation reported $96.6 million collaborative revenue with its partner Astellas Pharma for Xtandi.
Medivation Management Discusses Q4 2013 Results - Earnings Call Transcript
Good afternoon, and welcome to the Medivation's Fourth Quarter and Year End 2013 Financial Results Conference Call.
Medivation (MDVN) to Release Earnings on Thursday
Medivation is set to release its Q413 earnings data on Thursday, February 27th. Analysts expect Medivation to post earnings of per share and revenue of $72.68 million for the quarter.